Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by stock analysts at Deutsche Bank AG in a research report issued to clients and investors on Monday. They currently have a GBX 5,500 ($72.34) target price on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target would suggest a potential upside of 49.82% from the company’s current price.
Other research analysts have also issued research reports about the company. Liberum Capital reaffirmed a “buy” rating and set a GBX 4,200 ($55.24) target price on shares of Shire PLC in a report on Monday. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Shire PLC in a report on Friday, August 4th. Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Wednesday, September 20th. Barclays PLC reaffirmed an “equal weight” rating and set a GBX 4,000 ($52.61) target price on shares of Shire PLC in a report on Monday, October 30th. Finally, Kepler Capital Markets reaffirmed a “buy” rating and set a GBX 4,600 ($60.50) target price on shares of Shire PLC in a report on Wednesday, November 1st. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of GBX 5,272.22 ($69.34).
Shares of Shire PLC (LON:SHP) opened at GBX 3,671 ($48.28) on Monday. Shire PLC has a 52 week low of GBX 3,435.50 ($45.19) and a 52 week high of GBX 5,067 ($66.64).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.